ArticleCell reports. Medicine2020

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.

Wells S Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.